Education
About Us
Working with TipRanks
Follow Us
Heart Test Laboratories, Inc. (HSCS)
NASDAQ:HSCS
HSCS Stock Chart & Stats
$3.33
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.33
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$2.52 - $6.47
Previous CloseN/A
Volume8.49K
Average Volume (3M)72.64K
Market Cap
$9.02M
Enterprise Value$3.22M
Total Cash (Recent Filing)$2.79B
Total Debt (Recent Filing)$1.95B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Dec 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding2,647,712
10 Day Avg. Volume31,315
30 Day Avg. Volume72,638
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit2.74
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside215.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
AI And Technology AdvancementA multi-billion-dollar opportunity exists with its cloud platform to manage hospital ECGs and provide AI disease detection.
FDA Approval And Product LaunchHeartSciences is setting up for a large market opportunity, with the approval of the MyoVista device expected to complement the current rollout of MyoVista Insights cloud software platform.
Regulatory ProgressDuring the quarter, the company achieved an FDA breakthrough device designation and launched MyoVista Insights with early adopter reference sites.
Bears Say
Funding And Financial ChallengesMore financing is required due to the company's cash position and quarterly burn rate, indicating a need for substantial cash to finance its expected monetization phase.
Price Target AdjustmentThe price target has been reset to $9 from $15, reflecting the impact of share-count dilution on the net present value analysis.
Regulatory DelaysFDA submission for the MyoVista Insights software platform is now expected to be delayed to CY1H26, pushing out initial revenue projections to late CY26.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $2.52 and its highest was $6.47 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $9.02M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Dec 11, 2025 which is in 53 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Sep 11, 2025. The company reported -$1.735 earnings per share for the quarter, the consensus estimate of -$1.735 by $0.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 2,647,712 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$1.735 in its last earnings report, expectations of -$1.735. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
HSCS Stock 12 Month Forecast
Average Price Target
$10.50
▲(215.32% Upside)
Technical Analysis
Nuwellis
―
Sintx Technologies
―
Vyome Holdings
―
Venus Concept
―
Autonomix Medical, Inc.
―
Ownership Overview
0.47% Insiders
0.43% Mutual Funds
0.71% Other Institutional Investors
98.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---